Prevalence of high-risk HPV genotypes, categorised by their quadrivalent and nine-valent HPV vaccination coverage, and the genotype association with high-grade lesions

Table 4 Associations and impact between the risk intraepithelial lesion/malignancy and the vaccine-targeted high-risk HPV genotypes

		No lesion	Intraepithelial lesion or malignancy^a
		n = 509	n = 81	ORc	95%CI		ORa	95%CI		AFe-a	95%CI
Regarding HPV genotype
No high-risk^b		154	6	1	–		1	–
At least 1 high-risk		355	75	5.42	2.31	12.72	6.01	2.53	14.29	0.83	0.60	0.93
According to the vaccine-targeted high-risk HPV genotypes
No high-risk^b		154	6	1	–		1	–
Quadrivalent HPV non-vaccine-targeted high-risk HPV genotypes^c		208	20	2.47	0.97	6.29	2.71	1.05	7.01	0.63	0.04	0.86
	Quadrivalent HPV and nine-valent HPV non-vaccine-targeted high-risk HPV genotypes^d	101	6	1.53	0.48	4.86	1.76	0.54	5.70	0.43	–	–
	Additional five high-risk HPV genotypes present in the nine-valent HPV vaccine^e	107	14	3.36	1.25	9.02	3.51	1.29	9.56	0.72	0.22	0.90
Vaccine-targeted high-risk HPV genotypes (16 or 18)		145	52	9.21	3.84	22.08	10.40	4.25	25.40	0.90	0.76	0.96
Vaccine-targeted high-risk HPV genotypes (16 and 18)		2	3	38.50	5.39	275.06	63.58	8.62	468.70	0.98	0.88	1.00
				< 0.001			< 0.001

^aIntraepithelial lesion or malignancy: high-grade squamous intraepithelial lesion or worse
Odds ratio and 95% confidence intervals. ORc denotes “crude OR”; ORa denotes “adjusted OR” OR adding to the basic model: age and immigrant status
AFe-a: Attributable fraction among the exposed, adjusted for age and immigrant status
^bNo high-risk. Classification of human papillomavirus (HPV) types according to the World Health Organization International Agency for Research on Cancer (IARC) Monographs Working Group assessment of the carcinogenicity of different HPV types [25,26,27]
^cAt least 1 of the quadrivalent HPV non-vaccine-targeted high-risk HPV genotypes (31 or 33 or 35 or 39 or 45 or 51 or 52 or 56 or 58 or 59 or 68)
^dAt least 1 of the quadrivalent HPV and nine-valent HPV non-vaccine-targeted high-risk HPV genotypes (35 or 39 or 51 or 56 or 59 or 68)
^eAt least 1 of the additional five high-risk HPV genotypes present in the nine-valent HPV vaccine (31 or 33 or 45 or 52 or 58)

ISSN: 1471-2407